Novo Nordisk has entered into a significant research partnership with Seattle-based genomics startup Variant Bio, in a deal that could reach $50 million. The collaboration aims to advance the study and treatment of metabolic disorders, including obesity and diabetes, through innovative genomic research.
Variant Bio, established in 2018, distinguishes itself through its unique approach to genetic research, partnering with Indigenous populations worldwide to create more comprehensive genetic databases. This strategy addresses a crucial gap in current medical research, which has historically concentrated on individuals of European descent.
The company’s chief scientist, David Moller, emphasized the importance of expanding genetic research beyond traditional populations. By analyzing diverse genetic variations and their relationships to metabolic characteristics, the company aims to discover new
therapeutic targets and develop more inclusive treatment options for global populations.
Operating from their Seattle headquarters, which features a Space Needle-visible rooftop deck, the 40-person company has developed a sophisticated platform that combines statistical genetics with machine learning to identify promising treatment pathways.
Stephane Castel, who co-founded Variant Bio and serves as its chief technologist, views the Novo Nordisk partnership as a crucial milestone. The collaboration with an established leader in metabolic disease research significantly enhances their ability to transform genetic discoveries into practical medical treatments.
Central to Variant Bio’s mission is its ethical framework for genetic research. The company has implemented a comprehensive benefit-sharing program that ensures participating communities receive tangible advantages from their contributions to genetic research. This includes guarantees of affordable access to any developed treatments and direct financial benefits.
The company’s commitment to ethical practices includes allocating 10% of each study’s budget (up to $100,000 per project) to support local initiatives in partner communities, focusing on health, environmental, educational, and cultural programs. Additionally, Variant Bio pledges 4% of its annual net revenue to these communities and has established provisions for sharing proceeds from potential acquisition or public offering scenarios.
This approach represents a significant departure from historical practices in genetic research, where communities providing genetic information often received minimal benefits from their participation. Variant Bio’s model ensures that partner communities are treated as valuable stakeholders in the research process.
The startup has demonstrated strong financial backing, having secured $130 million in investor funding prior to this partnership. The collaboration with Novo Nordisk not only provides additional resources but also validates Variant Bio’s innovative approach to genetic research and drug development.
The partnership extends over multiple years and focuses on leveraging genomic information to develop new treatments for metabolic
conditions. By combining Variant Bio’s genetic research capabilities with Novo Nordisk’s expertise in drug development, the collaboration aims to accelerate the discovery and development of novel therapeutic approaches.
Through this strategic alliance, Variant Bio continues to advance its mission of expanding the scope of genetic research while maintaining ethical partnerships with diverse communities worldwide. The company’s commitment to both scientific innovation and social responsibility positions it uniquely in the biotechnology sector, working to ensure that advances in genetic medicine benefit a broader spectrum of the global population.